NCT01650545View on ClinicalTrials.gov

Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

August 31, 2015

Study Completion Date

November 30, 2019

Conditions
Disorder Related to Lung TransplantationBronchiolitis ObliteransDecreased Immunologic ActivityChronic Rejection of Lung Transplant
Interventions
DRUG

Liposomal aerosol cyclosporine

inhaled form of immune suppression

OTHER

standard immune suppression, oral

"conventional drug~Conventrional oral immune suppression as standard of care thus consists of tacrolimus, mycophenolate mofetil prednisone and rapamycin"

Trial Locations (1)

21201

University of Maryland Medical Center, Baltimore

All Listed Sponsors
lead

University of Maryland, Baltimore

OTHER

NCT01650545 - Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients | Biotech Hunter | Biotech Hunter